Clinical Trial

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (ALL).
Protocol Amendment History 22 amendments
This ClinicalTrials.gov record has been amended 22 times since 2020-05-25; most recent amendment 2026-04-02.
Status change: Recruiting → Active, Not Recruiting 2023-06-08
Trial Details
NCT Number NCT04404660
Lead Sponsor Autolus Limited
Conditions Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Enrollment 153 participants
Start Date 2020-06-03
Primary Completion 2029-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-08